Voriconazole

pharmacological · digestive · immune-hematologic · Oral · IV

Voriconazole. Second-gen triazole; extended-spectrum antifungal (Aspergillus, Fusarium, Scedosporium). Strong CYP2C19 + CYP2C9 + CYP3A4 inhibitor.… Oral half-life 6 h.

Second-gen triazole; extended-spectrum antifungal (Aspergillus, Fusarium, Scedosporium). Strong CYP2C19 + CYP2C9 + CYP3A4 inhibitor. CYP2C19 polymorphism drives extreme exposure variability — TDM strongly recommended. Visual disturbances (~30%) at therapeutic levels.

INTERACTIONS: TWO OF FOUR INVERT THROUGH 8 µM, one of them stating it outright. THE OTHER TWO BOTH IMPLY A NINE-FOLD RISE THAT NEITHER SOURCE STATES — tacrolimus cites 6.02-fold and alfentanil an 85 percent clearance fall, which is 6.67-fold — so two independent edges were adjusted to the same wrong place, which is more suggestive than one but still not a finding. Left alone.

Related compounds

• Tacrolimus — major
• Cyclosporine — major
• Midazolam — major
• Alfentanil — major
• Omeprazole — warn
• Sirolimus — contraindicated

Sources: PMID:11956505, PMID:16580904, PMID:17112806